Jun-Lin Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jun-Lin Jiang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Nian-Sheng Li
Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
5 shared publicationsGe Li
Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China; Department of Basic Medicine, Zhaoqing Medical College, Zhaoqing, 526020, China
4 shared publicationsLi Yan
Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410078, China; Department of Pharmacy, Wuhan Asia General Hospital, Wuhan, 430056, China
4 shared publicationsNiansheng Li
4 shared publicationsXu Xie
Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
4 shared publications- Yuan-Jian Li
Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410078, China
4 shared publications
Latest Publications
- Open Access
A Ferrous‐Supply‐Regenerating Lipid Nanoparticle Integrating RNAi Induces Ferroptosis for Cancer Therapy
Targeting iron‐dependent ferroptosis with siRNA has emerged as a promising strategy for cancer treatment. The concept of ferrous‐supply regeneration, inspired by electro‐Fenton technology, has also gained interest as a non‐apoptotic approach to induce ferroptosis. However, integrating both strategies into a single lipid nanoparticle (LNP) remains challenging. To address this, we developed ALSF, a novel LNP in which DSPC is replaced with arachidonic acid (AA) to enable co‐delivery of Glutathione Peroxidase 4‐siRNA (GPX4‐siRNA) and Fe 3 + . ALSF facilitates acid‐ and H 2 O 2 ‐dependent iron recycling, continuously regenerating Fe 2 + to drive ROS production, while GPX4‐siRNA silences GPX4 to induce lipid peroxidation (LPO) and ferroptosis. Elevated H 2 O 2 levels in cancer cells promote selective iron recycling, lysosomal disruption, and siRNA escape, enabling effective gene knockdown at lower doses. In vivo, ALSF suppressed tumor growth in a C918 xenograft model with favorable biosafety. This study is the first to integrate a ferrous‐supply‐regeneration system with siRNA into a single LNP platform, offering a selective ferroptosis‐inducing strategy for ocular cancers and other ferroptosis‐sensitive malignancies.
Open AccessA Ferrous‐Supply‐Regenerating Lipid Nanoparticle Integrating RNAi Induces Ferroptosis for Cancer Therapy
Targeting iron‐dependent ferroptosis with siRNA has emerged as a promising strategy for cancer treatment. The concept of ferrous‐supply regeneration, inspired by electro‐Fenton technology, has also gained interest as a non‐apoptotic approach to induce ferroptosis. However, integrating both strategies into a single lipid nanoparticle (LNP) remains challenging. To address this, we developed ALSF, a novel LNP in which DSPC is replaced with arachidonic acid (AA) to enable co‐delivery of Glutathione Peroxidase 4‐siRNA (GPX4‐siRNA) and Fe 3 + . ALSF facilitates acid‐ and H 2 O 2 ‐dependent iron recycling, continuously regenerating Fe 2 + to drive ROS production, while GPX4‐siRNA silences GPX4 to induce lipid peroxidation (LPO) and ferroptosis. Elevated H 2 O 2 levels in cancer cells promote selective iron recycling, lysosomal disruption, and siRNA escape, enabling effective gene knockdown at lower doses. In vivo, ALSF suppressed tumor growth in a C918 xenograft model with favorable biosafety. This study is the first to integrate a ferrous‐supply‐regeneration system with siRNA into a single LNP platform, offering a selective ferroptosis‐inducing strategy for ocular cancers and other ferroptosis‐sensitive malignancies.
- Open Access
- 1 January 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (1) , 24
Relationship between vascular calcification assessed by chest CT and CHA2DS2-VASc score in patients with atrial fibrillation receiving oral anticoagulant
The CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years (2 points), diabetes, previous stroke/transient ischemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years, and female sex] score is a well-established tool for stratifying thromboembolic risk in atrial fibrillation (AF) patients and identifying those suitable for initiation of oral anticoagulant (OAC) therapy. Patients with AF requiring anticoagulation are often at high risk for vascular calcification (VC). However, the relationship between the CHA2DS2-VASc score and VC, particularly in patients receiving OACs, remains poorly understood. This study aimed to evaluate the burden of VC according to the baseline CHA2DS2-VASc score and to explore its relationship with OAC use. A total of 1,288 AF patients were categorized based on the presence or absence of VC assessed by computed tomography (CT). Clinical characteristics, CHA2DS2-VASc scores, and major adverse cardiovascular events (MACEs) were compared between these groups. The differential effects of warfarin and direct oral anticoagulants (DOACs) on VC burden were further evaluated. A positive correlation was observed between the CHA2DS2-VASc score and the prevalence and severity of VC. Crucially, there was a greater burden of calcification in patients with a low CHA2DS2-VASc score of the rivaroxaban group (P=0.020) and the warfarin group (P=0.021) than in the non-anticoagulant group. Further, we found that patients in the rivaroxaban group had more severe calcification in the thoracic aorta (P=0.044), and the warfarin group’s calcification burden was greatest in the left subclavian artery (P=0.027) and coronary arteries (P=0.001). The multivariate Cox regression analysis indicated that MACEs were nearly threefold more frequent in the high CHA2DS2-VASc score group compared to the low score group (P=0.005). In AF patients receiving OACs, higher CHA2DS2-VASc scores are associated with an increased prevalence and severity of VC, as well as a higher frequency of MACEs.
- 1 January 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (1) , 24
Open AccessRelationship between vascular calcification assessed by chest CT and CHA2DS2-VASc score in patients with atrial fibrillation receiving oral anticoagulant
The CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years (2 points), diabetes, previous stroke/transient ischemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years, and female sex] score is a well-established tool for stratifying thromboembolic risk in atrial fibrillation (AF) patients and identifying those suitable for initiation of oral anticoagulant (OAC) therapy. Patients with AF requiring anticoagulation are often at high risk for vascular calcification (VC). However, the relationship between the CHA2DS2-VASc score and VC, particularly in patients receiving OACs, remains poorly understood. This study aimed to evaluate the burden of VC according to the baseline CHA2DS2-VASc score and to explore its relationship with OAC use. A total of 1,288 AF patients were categorized based on the presence or absence of VC assessed by computed tomography (CT). Clinical characteristics, CHA2DS2-VASc scores, and major adverse cardiovascular events (MACEs) were compared between these groups. The differential effects of warfarin and direct oral anticoagulants (DOACs) on VC burden were further evaluated. A positive correlation was observed between the CHA2DS2-VASc score and the prevalence and severity of VC. Crucially, there was a greater burden of calcification in patients with a low CHA2DS2-VASc score of the rivaroxaban group (P=0.020) and the warfarin group (P=0.021) than in the non-anticoagulant group. Further, we found that patients in the rivaroxaban group had more severe calcification in the thoracic aorta (P=0.044), and the warfarin group’s calcification burden was greatest in the left subclavian artery (P=0.027) and coronary arteries (P=0.001). The multivariate Cox regression analysis indicated that MACEs were nearly threefold more frequent in the high CHA2DS2-VASc score group compared to the low score group (P=0.005). In AF patients receiving OACs, higher CHA2DS2-VASc scores are associated with an increased prevalence and severity of VC, as well as a higher frequency of MACEs.
- Open Access
- 29 September 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-15
Long non-coding RNA HMGCR suppresses vascular remodeling in streptozotocin-induced type 1 diabetic rats via interaction with THOC5
This study aimed to investigate the role of long non-coding RNA (lncRNA) in vascular smooth muscle cell (VSMC) dysfunction under diabetic conditions, with a specific focus on lncHMGCR and its regulatory effects on VSMC proliferation and migration using streptozotocin-induced type 1 diabetic (T1DM) rat model and primary rat VSMCs stimulated with high glucose. Transcriptome sequencing (RNA-seq) was performed to identify differentially expressed lncRNAs in the aortic tissues of T1DM rats. Functional enrichment analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, was conducted to elucidate potential biological roles. The expression of lncHMGCR was validated via quantitative real-time polymerase chain reaction (qRT-PCR) in the aortic tissues of T1DM rats and primary rat VSMCs pretreated with high glucose (30 mM). Functional assays were carried out to evaluate the effects of lncHMGCR overexpression and THOC5 silencing on VSMC proliferation and migration under high glucose conditions. RNA-seq analysis identified 229 differentially expressed lncRNAs (180 upregulated and 49 downregulated) in diabetic aortic tissues. GO and KEGG analyses revealed enrichment in transcriptional regulation, metal ion binding, and glycolysis-related pathways. LncHMGCR was significant downregulated in both diabetic aortic tissues and VSMCs stimulated with high glucose. Functional studies demonstrated that lncHMGCR overexpression inhibited high glucose-induced VSMC proliferation and migration by restoring THOC5 expression, whereas THOC5 knockdown exacerbated these effects. This study demonstrates that lncHMGCR suppresses VSMCs dysfunction under diabetic conditions by upregulating THOC5 expression, suggesting its potential as a therapeutic target for vascular remodeling in T1DM. However, these findings are based solely on animal models and in vitro experiments, and further validation in clinical samples is required to confirm translational relevance.
- 29 September 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-15
Open AccessLong non-coding RNA HMGCR suppresses vascular remodeling in streptozotocin-induced type 1 diabetic rats via interaction with THOC5
This study aimed to investigate the role of long non-coding RNA (lncRNA) in vascular smooth muscle cell (VSMC) dysfunction under diabetic conditions, with a specific focus on lncHMGCR and its regulatory effects on VSMC proliferation and migration using streptozotocin-induced type 1 diabetic (T1DM) rat model and primary rat VSMCs stimulated with high glucose. Transcriptome sequencing (RNA-seq) was performed to identify differentially expressed lncRNAs in the aortic tissues of T1DM rats. Functional enrichment analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, was conducted to elucidate potential biological roles. The expression of lncHMGCR was validated via quantitative real-time polymerase chain reaction (qRT-PCR) in the aortic tissues of T1DM rats and primary rat VSMCs pretreated with high glucose (30 mM). Functional assays were carried out to evaluate the effects of lncHMGCR overexpression and THOC5 silencing on VSMC proliferation and migration under high glucose conditions. RNA-seq analysis identified 229 differentially expressed lncRNAs (180 upregulated and 49 downregulated) in diabetic aortic tissues. GO and KEGG analyses revealed enrichment in transcriptional regulation, metal ion binding, and glycolysis-related pathways. LncHMGCR was significant downregulated in both diabetic aortic tissues and VSMCs stimulated with high glucose. Functional studies demonstrated that lncHMGCR overexpression inhibited high glucose-induced VSMC proliferation and migration by restoring THOC5 expression, whereas THOC5 knockdown exacerbated these effects. This study demonstrates that lncHMGCR suppresses VSMCs dysfunction under diabetic conditions by upregulating THOC5 expression, suggesting its potential as a therapeutic target for vascular remodeling in T1DM. However, these findings are based solely on animal models and in vitro experiments, and further validation in clinical samples is required to confirm translational relevance.
- 28 August 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 983, 176961
The role of cardiomyocyte senescence in cardiovascular diseases: A molecular biology update
- 28 August 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 983, 176961
The role of cardiomyocyte senescence in cardiovascular diseases: A molecular biology update
- 15 September 2022
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 39 (6) , 747-758
6-O-desulfated heparin attenuates myocardial ischemia/reperfusion injury in mice through the regulation of miR-199a-5p/klotho axis
Heparin has been documented to reduce myocardial injury caused by ischemia/reperfusion (I/R), but its clinical application is limited due to its strong intrinsic anticoagulant property. Some desulfated derivatives of heparin display low anticoagulant activity and may have potential value as therapeutic agents for myocardial I/R injury. In this study, we observed that 6-O-desulfated heparin, a desulfated derivative of heparin, shortened the activated partial thromboplastin time and exhibited lower anticoagulant activity compared with heparin or 2-O-desulfated heparin (another desulfated derivative of heparin). Then, we explored whether 6-O-desulfated heparin could protect against myocardial I/R injury, and elucidated its possible mechanisms. Administration of 6-O-desulfated heparin significantly reduced creatine kinase activity, myocardial infarct size and cell apoptosis in mice subjected to 30 min of myocardial ischemia following 2 h of reperfusion, accompanied by a reverse in miR-199a-5p elevation, klotho downregulation and reactive oxygen species (ROS) accumulation. In cultured H9c2 cells, the mechanism of 6-O-desulfated heparin against myocardial I/R injury was further explored. Consistent with the results in vivo, 6-O-desulfated heparin significantly ameliorated hypoxia/reoxygenation-induced injury, upregulated klotho and decreased miR-199a-5p levels and ROS accumulation, and these effects were reversed by miR-199a-5p mimics. In conclusion, these results suggested that 6-O-desulfated heparin with lower anticoagulant activity attenuated myocardial I/R injury through miR-199a-5p/klotho and ROS signaling. Our study may also indicate that 6-O-desulfated heparin, as an excellent heparin derivative, is a potential therapeutic agent for myocardial I/R injury.
- 15 September 2022
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 39 (6) , 747-758
6-O-desulfated heparin attenuates myocardial ischemia/reperfusion injury in mice through the regulation of miR-199a-5p/klotho axis
Heparin has been documented to reduce myocardial injury caused by ischemia/reperfusion (I/R), but its clinical application is limited due to its strong intrinsic anticoagulant property. Some desulfated derivatives of heparin display low anticoagulant activity and may have potential value as therapeutic agents for myocardial I/R injury. In this study, we observed that 6-O-desulfated heparin, a desulfated derivative of heparin, shortened the activated partial thromboplastin time and exhibited lower anticoagulant activity compared with heparin or 2-O-desulfated heparin (another desulfated derivative of heparin). Then, we explored whether 6-O-desulfated heparin could protect against myocardial I/R injury, and elucidated its possible mechanisms. Administration of 6-O-desulfated heparin significantly reduced creatine kinase activity, myocardial infarct size and cell apoptosis in mice subjected to 30 min of myocardial ischemia following 2 h of reperfusion, accompanied by a reverse in miR-199a-5p elevation, klotho downregulation and reactive oxygen species (ROS) accumulation. In cultured H9c2 cells, the mechanism of 6-O-desulfated heparin against myocardial I/R injury was further explored. Consistent with the results in vivo, 6-O-desulfated heparin significantly ameliorated hypoxia/reoxygenation-induced injury, upregulated klotho and decreased miR-199a-5p levels and ROS accumulation, and these effects were reversed by miR-199a-5p mimics. In conclusion, these results suggested that 6-O-desulfated heparin with lower anticoagulant activity attenuated myocardial I/R injury through miR-199a-5p/klotho and ROS signaling. Our study may also indicate that 6-O-desulfated heparin, as an excellent heparin derivative, is a potential therapeutic agent for myocardial I/R injury.
- 1 February 2022
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 141, 104636
Network pharmacology-based analysis of the anti-hyperglycemic active ingredients of roselle and experimental validation
- 1 February 2022
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 141, 104636
Network pharmacology-based analysis of the anti-hyperglycemic active ingredients of roselle and experimental validation
- 1 October 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 908, 174317
Involvement of miR-199a-3p/DDR1 in vascular endothelial cell senescence in diabetes
- 1 October 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 908, 174317
Involvement of miR-199a-3p/DDR1 in vascular endothelial cell senescence in diabetes
- 1 October 2019
- Published by Springer Nature in Amino Acids
- Vol. 51 (10-12) , 1515-1526
Asymmetric dimethylarginine aggravates blood–retinal barrier breakdown of diabetic retinopathy via inhibition of intercellular communication in retinal pericytes
Blood–retinal barrier breakdown is the main pathological characteristics of diabetic retinopathy (DR). Asymmetric dimethylarginine (ADMA) was reported to be elevated in DR patients. In this study, we observed the dynamic profile of ADMA, retinal morphology and permeability of BRB at 2, 4 or 8 week of diabetic rats induced by a single intraperitoneal injection of streptozocin (60 mg/kg) and in cultured rat retinal pericytes pretreated with d-glucose (30 mM) for 1, 3, 5 and 7 days or ADMA (3, 10, 30 μM) for 24, 48 and 72 h, trying to explore the effects of ADMA on blood–retinal barrier in DR. Gap junction intercellular communication (GJIC) and the expression of blood–retinal barrier-specific component connexin 43 (Cx43) were examined in diabetic rats or cultured retinal pericytes to elucidate whether ADMA impacted blood–retinal barrier function via damaging Cx43-GJIC. The results showed that with increasing duration of diabetes, the ultrastructure of blood–retinal barrier of diabetic rats appeared cell junction damage, apoptosis of retinal pericytes and breakdown of barrier successively. The increases in retinal permeability, ADMA levels and Cx43 expression, and abnormal GJIC were observed in diabetic rats and retinal pericytes exposed to d-glucose (30 mM). A glucose-like effect was seen using ADMA or another l-arginine analogue NG-monomethyl-l-arginine or dimethylarginine dimethylaminohydrolases (DDAHs) siRNA, implicating that ADMA aggravated the breakdown of blood–retinal barrier via damaging Cx43-GJIC.
- 1 October 2019
- Published by Springer Nature in Amino Acids
- Vol. 51 (10-12) , 1515-1526
Asymmetric dimethylarginine aggravates blood–retinal barrier breakdown of diabetic retinopathy via inhibition of intercellular communication in retinal pericytes
Blood–retinal barrier breakdown is the main pathological characteristics of diabetic retinopathy (DR). Asymmetric dimethylarginine (ADMA) was reported to be elevated in DR patients. In this study, we observed the dynamic profile of ADMA, retinal morphology and permeability of BRB at 2, 4 or 8 week of diabetic rats induced by a single intraperitoneal injection of streptozocin (60 mg/kg) and in cultured rat retinal pericytes pretreated with d-glucose (30 mM) for 1, 3, 5 and 7 days or ADMA (3, 10, 30 μM) for 24, 48 and 72 h, trying to explore the effects of ADMA on blood–retinal barrier in DR. Gap junction intercellular communication (GJIC) and the expression of blood–retinal barrier-specific component connexin 43 (Cx43) were examined in diabetic rats or cultured retinal pericytes to elucidate whether ADMA impacted blood–retinal barrier function via damaging Cx43-GJIC. The results showed that with increasing duration of diabetes, the ultrastructure of blood–retinal barrier of diabetic rats appeared cell junction damage, apoptosis of retinal pericytes and breakdown of barrier successively. The increases in retinal permeability, ADMA levels and Cx43 expression, and abnormal GJIC were observed in diabetic rats and retinal pericytes exposed to d-glucose (30 mM). A glucose-like effect was seen using ADMA or another l-arginine analogue NG-monomethyl-l-arginine or dimethylarginine dimethylaminohydrolases (DDAHs) siRNA, implicating that ADMA aggravated the breakdown of blood–retinal barrier via damaging Cx43-GJIC.
- 1 July 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 854, 54-61
Asymmetric dimethylarginine: An crucial regulator in tissue fibrosis
- 1 July 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 854, 54-61
Asymmetric dimethylarginine: An crucial regulator in tissue fibrosis